Drugs / RO7283420
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04580121 | Nov 2020 → Aug 2023 | acute myeloid leukemia | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7283420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04580121 ↗ |
| Action | Deplete | “WT1-TCB facilitates potent in vitro, ex vivo, and in vivo killing of AML cell lines and primary AML cells” PMID 34280257 ↗ Dec 2021 |
| Route | Intravenous | “RO7283420 will be administered to participants by intravenous (IV) infusion Q3W” NCT04580121 ↗ |
| Target | WT1 | “recognizes the RMFPNAPYL peptide derived from the intracellular tumor antigen Wilms tumor protein (WT1)” PMID 34280257 ↗ Dec 2021 |